News & Blog


    Public health advocates have been concerned about rising e-cigarette use (“vaping”) among teens. For the first time in 2014, teens reported being more likely to use e-cigarettes than regular cigarettes. New Jersey implemented the first law restricting the purchase of e-cigarettes or other electronic nicotine delivery systems (ENDS) in 2010; almost all states followed suit […]

    Read the full story

    The Kaiser Commission on Medicaid and the Uninsured recently released an issue brief detailing the most costly outpatient drugs to Medicaid in 2014 and the first half of 2015. Using data from the Center for Medicare and Medicaid Services (CMS), the authors analyzed outpatient drug costs based on Medicaid spending (before rebates) to determine which […]

    Read the full story

    PA Governor Tom Wolf Urges Medical Professionals to Sign Up   Photo: Hoag Levins Pennsylvania Governor Tom Wolf speaks at a University of Pennsylvania press conference where he announced the launch of a new state prescription drug monitoring system designed to tighten access to prescription opioid drugs and other controlled substances. Pennsylvania Governor Tom Wolf […]

    Read the full story

    By Hoag Levins 36-Month Study to Focus on Opioid Risk Communications in Clinical Settings University of Pennsylvania Assistant Professor of Emergency Medicine and LDI Senior Fellow Zachary Meisel, MD, has received a $2.1 million funding award from the Patient-Centered Outcomes Research Institute (PCORI). The award will fund a 36-month comparative effectiveness study of enhanced opioid risk […]

    Read the full story

    Two weeks ago, the Department of Health and Human Services (DHHS) announced changes in buprenorphine treatment regulations that would allow certain licensed physicians to provide buprenorphine to up to 275 patients. This is an increase from the 100 patient limit set forth by the Office of National Drug Control Policy (ONDCP) Reauthorization Act of 2006. The […]

    Read the full story

    Following approval by the US Food and Drug Administration (FDA), probuphine will become the latest medication-assisted treatment (MAT) option to treat opioid use disorders in the United States. Probuphine is a subdermal implant that consists of four one-inch rods that deliver a daily dose of 8 mg of buprenorphine, an opioid agonist that staves off […]

    Read the full story